Erratum to: Analysis of Prognostic Factors in Extraosseous Ewing Sarcoma Family of Tumors: Review of St. Jude Children’s Research Hospital Experience

Abstract

In the original publication, the first author's surname is captured incorrectly. The correct name is Orr, W. Shannon.

Extraskeletal Ewing Sarcomas in Late Adolescence and Adults: A Study of 37 Patients

“…However, Locations in the extremities were also observed in some other reports (Rud et al, 1989;Kaspers et al, 1991). The median tumour size of this series is 8.2 cm, which is similar to other reported series presenting a range of 6.5-11 cm, but the incidence of distant metastases in our series is the highest reported in published studies, nearly half of patients got metastatic disease (Rud et al, 1989;Baldini et al, 1999;El et al, 2010;Shannon et al, 2012;Tural et al, 2012). Those difficult cases are more likely to send to our hospital, what makes selection bias.…”

“…Radiotherapy may also have a role in improving local disease control in patients with poor chemotherapeutic response (Dunst et al, 2004). Only 13 patients (35.1%) in our study received radiotherapy and 8 was performed in localized disease, the local control was not so satisfied in this series comparing with others studies (Raney et al, 1997;Gururangan et al, 1998;El et al, 2010;Applebaum et al, 2011;Shannon et al, 2012;Tural et al, 2012), the median time to local recurrence was 18.1 months, 60% of the patients with localized disease got recurrence and only 6 patients (30%) with no progression. Most of our cases (64%) had truck lesions and radical surgery was difficult.…”

“…Although the fact that all EFST share a common genetic basis, there is still some debate about whether we should use the same therapeutic approach as with classic Ewing sarcoma of bone (Zagar et al, 2008). Recently, two researches have confirmed that patients with EES fare well with the same tumour characteristics and treatment as with ESFT (Gururangan et al, 1998;Shannon et al, 2012). It is widely recognized that EFST are, indeed, systemic diseases at presentation, even if documented metastases are not found (Zagar et al, 2008).The application of adjuvant chemotherapy, which began in the early of 1970s, has greatly improved survival rates for patients with localized ESFT, from about 10% to 70-80% (Balamuth et al, 2010).…”

“…Several studies have demonstrated the prognostic impacts on tumour stages (localized vs metastatic), sizes, surgical margins, high lactate dehydrogenase, present of CR to initial treatment (Kinsella et al, 1983;Rud et al, 1989;Raney et al, 1997;Ahmad et al, 1999;Eralp et al, 2002;El et al, 2010;Applebaum et al, 2011;Shannon et al, 2012;Tural et al, 2012).…”

Treatment and Outcomes of Ewing Sarcoma in Turkish Adults: A Single Centre Experience

“…But the results are conflicting (Oberlin et al, 2001;Grier et al, 2003;Kolb et al, 2003). Currently, the only evidence-based prognostic factor accepted by all authors is the presence of metastatic disease (Cotterill et al, 2000;van Doorninck et al, 2010;Shannon Orr et al, 2012). In our study, there was no correlation between gender, tumor size, and overall and disease-free survival.…”